Wolfgang Miesbach: Jan Astermark at the BIC 2025 Presented Potentially the First Oral FVIII Mimetic Treatment for Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on Linkedin:
”For decades, oral protein delivery has failed.
Jan Astermark at the BIC meeting 2025 presented comprehensive information on oral factor VIII bispecific treatment for haemophilia A – potentially the first oral FVIII mimetic treatment!
Why is this so groundbreaking?
For decades, oral protein delivery has failed due to three major barriers:
- Large molecular size (poor absorption/bioavailability)
- GI instability (narrow pH tolerance, variable factors)
- High hydrophilicity (can’t cross membrane barriers)
This innovative Inno8 approach systematically addresses each challenge: ✨
- Optimized size (~30 kDa) via albumin binding technology
- Enhanced stability through protraction and pH optimization
- SNAC absorption enhancement for membrane permeability
- Extended half-life (115h terminal half-life!)
- Once-daily dosing potential with reduced variability
Inno8 successfully balances all critical aspects for an oral hemophilia drug – Size ✓ Potency ✓Stability ✓ PK ✓ – currently advancing through Phase 1 clinical trials for both patients with and without inhibitors.”
Stay updated on all coming congresses and seminars in the field of bleeding disorders with Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25